This week we look at how bad the lockdown is affecting low-income families, and ask why after so many months Vitamin D has been ignored. As well as Low Dose Aspirin has a powerful benefit against COVID. #aspirin #covid #lockdown Study finds over 80% of COVID-19 patients have vitamin D deficiency https://www.eurekalert.org/pub_releases/2020-10/tes-sfo102220.php#.X5ibhuBizBU.wordpress Death rates among people with severe COVID-19 drop by a half in England https://www.eurekalert.org/pub_releases/2020-10/uoe-dra102720.php#.X5iZJ_Rg_T8.wordpress New study: aspirin use reduces risk of death in hospitalized patients https://www.eurekalert.org/pub_releases/2020-10/uoms-nsa102220.php https://www.census.gov/data-tools/demo/hhp/#/?measures=EVR
Why Canadians were told to stop taking aspirin to prevent first heart attack, stroke
If you’ve never had a heart attack or stroke, you likely should not be taking aspirin to prevent them, according to new research. Researchers reviewed three large, randomized, placebo-controlled studies published in 2018 that showed the risk of major internal bleeding associated with taking an aspirin a day is higher than any preventative benefits.
#aspirin #heart #stroke
Acetylsalicylic acid for primary prevention of cardiovascular events Paul Fritsch, Michael R. Kolber Canadian Family Physician Jul 2019, 65 (7) 480;
Daily Aspirin and younger women a bad mix
– ” they conclude that blanket treatment “is ineffective or harmful in the majority of women with regard to the combined risk of cardiovascular disease, cancer and major gastrointestinal bleeding.”
– Cons of regular low-dose aspirin to stave off serious illness in women outweigh pros published online in the journal Heart Dec 2014. Continue reading “Daily Aspirin and younger women a bad mix”
By JACK BOUBOUSHIAN
CHICAGO (CN) – Ten people died from the blockbuster blood-thinner Plavix, which is no better than aspirin against stroke but costs 100 times more, dozens of family members claim in two complaints.
Bristol-Myers Squibb and Sanofi-Aventis reaped annual U.S. sales of $3.8 billion from Plavix, pushing the drug in TV, magazine and Internet ads, while they “knew or should have known that when taking Plavix, the risk of suffering a heart attack, stroke, internal bleeding, blood disorder, or death far outweigh any potential benefit,” lead plaintiff Geraldine Jackson says.
At least 561 lawsuits have been filed over Plavix, according to the Courthouse News database. Rose Creighton is the lead plaintiff in the other most recently filed case. Both were filed in Cook County Court.
Quotations in this article are from Jackson’s lawsuit, though the dozens of plaintiffs make similar claims in both cases – that Bristol-Myers and Sanofi-Aventis deceived the public by misrepresenting the risks of Plavix, which they knew about from their own studies.
“Plavix was heavily marketed directly to consumers through television, magazine and Internet advertising,” the complaint states. “It was touted as a ‘super-aspirin,’ that would give a person even greater cardiovascular benefits than a much less expensive, daily aspirin while being safer and easier on a person’s stomach than aspirin. Those assertions have proven to be false.
“The truth is, that BMS and Sanofi always knew, or if they had paid attention to the findings of their own studies, should have known, that Plavix was not more efficacious than aspirin to prevent heart attacks and strokes. More importantly though, defendants knew or should have known that when taking Plavix, the risk of suffering a heart attack, stroke, internal bleeding, blood disorder, or death far outweigh any potential benefit.”
Plavix is the sixth best-selling drug in the United States, with annual sales of $3.8 billion, although it works no better than aspirin in many cases, according to the complaint. A dose of Plavix costs $4, 100 times more than aspirin, at 4 cents a dose.
“Defendants’ nearly eight-year run of lying to physicians and to the public about the safety and efficacy of Plavix for the sole purpose of increasing corporate profits has now been uncovered by scientific studies that reveal that not only is Plavix not worth its high price – it is dangerous,” the complaint states.
A recent study “uncovered another truth about Plavix,” the complaint adds. “It found that Plavix plus aspirin (dual therapy) is only minimally more effective than aspirin plus placebo at preventing atherothrombotic events. But more importantly, it found that in patients who do not have peripheral arterial disease (PAD) or acute coronary syndrome (ACS), Plavix plus aspirin (dual therapy) poses a 20 percent increased risk to the patient of suffering bleeding injuries, heart attacks, stroke and death. In other words, in those patients without ACS or PAD, dual therapy with aspirin and Plavix does more harm than good.
“Despite a growing body of scientific knowledge that the four-dollar ($4.00) Plavix pill was not much better than a four-cent-a-day aspirin, Defendants kept promoting it to the public and to physicians, using hyperbole and outright falsification in the process.”
Three people died because they took Plavix, according to Jackson’s lawsuit. Creighton’s lawsuit, filed the same day, claims that seven people died from the drug.
“Defendants failed to fully, truthfully and accurately communicate the safety and efficacy of Plavix drug products and intentionally and fraudulently misled the medical community, physicians, plaintiffs’ physicians and ingesting plaintiffs and decedents about the risks associated with Plavix,” Jackson’s complaint states.
The families seek punitive damages for products liability, manufacturing defect, failure to warn, negligence, loss of consortium and wrongful death.
All plaintiffs are represented by Steven Aroesty with Nafoli, Bern, Ripka, and Shkolnik, of Edwardsville, Ill.
Plavix has been prescribed to prevent stroke after operations, which may be caused by blood clots breaking loose and traveling toward the brain. It has been a drug of choice for conditions such as those being suffered by Secretary of State Hillary Clinton.
Mealworms for food
Aspirin Related to Age Related Macular Degeneration
Iodine and Pregnancy
CHICAGO ‑ Among nearly 5,000 study participants, regular aspirin use reported ten years prior was associated with a small but statistically significant increase in the risk of neovascular age‑related macular degeneration, according to a study in the December 19 issue of JAMA.
“Aspirin use in the United States is widespread, with an estimated 19.3 percent of adults reporting regular consumption, and reported use increases with age,” according to background information in the study. “The results of cross-sectional studies of aspirin use and its relation to age-related macular degeneration (AMD) have been inconsistent. AMD is a potentially blinding condition for which prevalence and incidence are increasing with the increased survival of the population, and regular use of aspirin is common and becoming more widespread in persons in the age range at highest risk for this disease. Therefore, it is imperative to further examine this potential association.”
Barbara E. K. Klein, M.D., M.P.H., of the University of Wisconsin School of Medicine and Public Health, Madison, and colleagues conducted a study to examine the association between aspirin use and AMD. The researchers used data from the Beaver Dam Eye Study, a longitudinal population-based study of age-related eye diseases conducted in Wisconsin. Examinations were performed every 5 years over a 20-year period (1988-1990 through 2008-2010). Study participants (n = 4,926) were 43 to 86 years of age at entry in the study. At subsequent examinations, participants were asked if they had regularly used aspirin at least twice a week for more than 3 months. The average duration of follow-up was 14.8 years.
For the study, the researchers measured the incidences of different types of AMD (early, late, and 2 subtypes of late AMD [neovascular AMD and pure geographic atrophy]).
There were 512 incident cases of early AMD and 117 incident cases of late AMD over the course of the study. The researchers found that regular use of aspirin use 10 years prior to the retinal examination was associated with late AMD (age- and sex-adjusted incidence, 1.8 percent for users vs. 1.0 percent for nonusers). When examining the relationships by late AMD subtype, neovascular AMD was significantly associated with such use (age-and sex-adjusted incidence, 1.4 percent for users vs. 0.6 percent for nonusers), but not for pure geographic atrophy. Aspirin use 5 years or 10 years prior to retinal examination was not associated with incident early AMD.
“Our findings are consistent with a small but statistically significant association between regular aspirin use and incidence of neovascular AMD. Additional replication is required to confirm our observations. If confirmed, defining the causal mechanisms may be important in developing methods to block this effect to prevent or retard the development of neovascular AMD in persons who use aspirin, especially to prevent CVD,” the authors conclude
2009 study posted for filing
The devastation of the 1918-1919 influenza pandemic is well known, but a new article suggests a surprising factor in the high death toll: the misuse of aspirin. Appearing in the November 1 issue of Clinical Infectious Diseases and available online now, the article sounds a cautionary note as present day concerns about the novel H1N1 virus run high.
High aspirin dosing levels used to treat patients during the 1918-1919 pandemic are now known to cause, in some cases, toxicity and a dangerous build up of fluid in the lungs, which may have contributed to the incidence and severity of symptoms, bacterial infections, and mortality. Additionally, autopsy reports from 1918 are consistent with what we know today about the dangers of aspirin toxicity, as well as the expected viral causes of death.
The motivation behind the improper use of aspirin is a cautionary tale, said author Karen Starko, MD. In 1918, physicians did not fully understand either the dosing or pharmacology of aspirin, yet they were willing to recommend it. Its use was promoted by the drug industry, endorsed by doctors wanting to “do something,” and accepted by families and institutions desperate for hope.
“Understanding these natural forces is important when considering choices in the future,” Dr. Starko said. “Interventions cut both ways. Medicines can save and improve our lives. Yet we must be ever mindful of the importance of dose, of balancing benefits and risks, and of the limitations of our studies.”
2009 study posted for filing
Individuals who take aspirin or other medications that prevent blood clotting by inhibiting the accumulation of platelets appear more likely to have tiny, asymptomatic areas of bleeding in the brain, according to a report posted online today that will appear in the June print issue of Archives of Neurology, one of the JAMA/Archives journals.
Cerebral microbleeds—small deposits of the iron-storing protein hemosiderin in the brain—may be a sign of cerebral small-vessel disease, according to background information in the article. This condition, common among older adults, occurs when the walls of blood vessels in the brain become weakened. When microbleeds occur in certain brain areas, they may indicate a type of small vessel disease known as cerebral amyloid angiopathy, in which the accumulation of amyloid (a protein often related to Alzheimer’s disease) causes degeneration of smooth muscle cells and increases the susceptibility of blood vessels to ruptures and hemorrhages.
Meike W. Vernooij, M.D., and colleagues at Erasmus MC University Medical Center, Rotterdam, the Netherlands, investigated the relationship between cerebral microbleeds and the use of anti-clotting medications in 1,062 individuals without dementia involved in the Rotterdam Scan Study. Participants (average age 69.6) underwent magnetic resonance imaging examinations in 2005 and 2006. Pharmacy records were used to assess whether any of the individuals took anti-clotting drugs. These included aspirin and carbasalate calcium—called platelet aggregation inhibitors because they prevent the accumulation of platelets that form blood clots.
In the years before MRI, 363 (34.2 percent) of the participants had used any anti-clotting drugs, including 245 (23.1 percent) who took platelet aggregation inhibitors (67 taking aspirin and 141 taking carbasalate calcium). Compared with patients who did not use anti-clotting drugs, those who took aspirin or carbasalate calcium were more likely to have cerebral microbleeds visible on MRI. This association was particularly strong among individuals taking these drugs at higher doses, typically used to treat or prevent heart disease. Microbleeds in the frontal lobe were more common among aspirin users than carbasalate calcium users. There was no association between other types of anti-clotting drugs and cerebral microbleeds.
“There is currently major interest in bleeding risks with the use of antithrombotic or thrombolytic treatment in persons who have microbleeds that are apparent on MRI because this may affect treatment in patients with cardiovascular or cerebrovascular disease,” the authors write. “The cross-sectional design of our analyses prohibited an investigation of whether persons with cerebral microbleeds are at increased risk for symptomatic hemorrhage [excessive bleeding] when using platelet aggregation inhibitors.”
The beneficial effects of anti-clotting drugs for individuals at risk for heart attack and stroke typically outweigh any risks of bleeding, they note. “Nevertheless, it may be that in selected persons (e.g., those with signs of cerebral amyloid angiopathy), this risk-benefit ratio may differ for certain drugs (e.g., aspirin), thus influencing treatment decision,” they conclude.
(Arch Neurol. 2009;66:(doi:10.1001/archneurol.2009.42). Available pre-embargo to the media at www.jamamedia.org.)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc
22-Dec-2008 posted for filing
WASHINGTON, Dec. 22, 2008 — Scientists in the United Kingdom are reporting new evidence that humans can make their own salicylic acid (SA) — the material formed when aspirin breaks down in the body. SA, which is responsible for aspirin’s renowned effects in relieving pain and inflammation, may be the first in a new class of bioregulators, according to a study scheduled for the Dec. 24 issue of ACS’ biweekly Journal of Agricultural and Food Chemistry.
In the report, Gwendoline Baxter, Ph.D. and colleagues discuss how their past research revealed that SA exists in the blood of people who have not recently taken aspirin. Vegetarians had much higher levels, almost matching those in patients taking low doses of aspirin. Based on those findings, the researchers previously concluded that this endogenous SA came from the diet, since SA is a natural substance found in fruits and vegetables.
Now the group reports on studies of changes in SA levels in volunteers who took benzoic acid, a substance also found naturally in fruits and vegetables that the body could potentially use to make SA. Their goal was to determine whether the SA found in humans (and other animals) results solely from consumption of fruits and vegetables, or whether humans produce their own SA as a natural agent to fight inflammation and disease. The results reported in the study suggest that people do manufacture SA.
“It is, we suspect, increasingly likely that SA is a biopharmaceutical with a central, broadly defensive role in animals as well as plants,” they state. “This simple organic chemical is, we propose, likely to become increasingly recognized as an animal bioregulator, perhaps in a class of its own.”